CEFPODOXIME combinations

CEFPODOXIME + CLAVULANIC ACID (In Resistance Cases) CEFPODOXIME + LEVOFLOXACIN (In AECB) CEFPODOXIME + DICLOXACILLIN ER (RTI,SSTI, Joint Infections)

CEFPODOXIME + OFLOXACIN (RTI, Typhoid Fever in Adults)

CEFPODOXIME + AZITHROMYCIN (Moderate to Severe RTI, CAP caused by Atypical Pathogens)

AVAILABLE COMPOSITIONS of CEFPODOXIME + CLAVULANIC ACID Cefpodoxime 200 mg + clavulanic acid 125 mg. (Film Coated Tablet) Cefpodoxime 100 mg + clavulanic acid 62.5 mg. (DT) Cefpodoxime 50 mg + clavulanic acid 31.25 mg/5 ml (DS) Cefpodoxime 50 mg + clavulanic acid 31.25 mg (DT)

Avg. PRICE 6's (119.4 INR)

6's (65.4 INR)

30ml (49 INR)

10's (59 INR)

CEFPODOXIME + CLAVULANIC ACID Indications as per DCGI

URTI & LRTI
UTI

Uncomplicated skin infection

AOM (Acute Otitis Media) Switch therapy after Parenteral Cephalosporins

CEFPODOXIME 200 mg + CLAVULANIC ACID 125 mg COMPITITORS

RANK
1 2 3

BRAND
CEFCHAMP CEPODEM XP GUDCEF CV

COMPANY
APHL RANBAXY MANKIND

PRICE
6's (162.22) 10s (299) 6's (119.94)

Value in cr.
20.14 16.78 14.99

Growth (%)
12.85 27.57 45.12

4
5 6 7 8 9 10 11 12 13

OPOX CV
DOXCEF CV CV CEF KEFPOD CV MONOCEF O CV MACPOD CV CLAVPOD ZIPOD CV AUGPOD PECEF DUO

HETERO
LUPIN BESTOCHEM GLENMARK ARISTO MACLEODS ALKEM FDC ELDER DRL

6's (119.94)
10s (280) 6's (155.94) 10's (186) 6's (150) 6's (118.68) 10's (270) 10's (220) 10's (250) ---

11.74
7.95 7.74 7.03 6.67 6.22 5.90 5.77 4.37 4.36

33.15
21.26 -17.43 20.13 36.95 87.71 -2.66 28.96 -22.56 13.83

AVERAGE

194.26

21.91

USP (CEFPODOXIME + CLAVULANIC ACID)

Broad spectrum of coverage.

Effective against -lactamase producing pathogens

More Potent to Co-Amoxiclav in RTI. Equally good coverage as that of Ceftriaxone, hence Ideal for Switching therapy.

Addition of clavulanic acid to Cefpodoxime reduces MIC level of Cefpodoxime

dramatically if bacteria is Producing -lactamase. More efficacious than Cefixime, due to its greater tissue penetration.

Enhanced Antistaphylococcal activity that distinguishes it from other orally active

third generation Cephalosporins. Safety Profile : Can be given to 20 days & above children

STRENGTHs (CEFPODOXIME + CLAVULANIC ACID)

Advantage of Wide Antibiotic Portfolio. Strong Customer Coverage GPs, ENT, PAED, PHY. High Market Growth Rate of combination 20%.

Highly Priced, Hence Contribution to company will be good.

High Acceptance from Medical Fraternity in RTI, AOM & SSTi. Potent to Cefixime & Co-Amoxiclav. Sales are not much affected by season.

TRAMADOL COMBINATIONS
DCGI APPROVED COMBINATIONS Tramadol Hcl 37.5mg+paracetamol 325mg tablet Tramadol Hcl IP (as immediate release layer) 50mg + Diclofenac sodium IP (as sustained release layer) 75mg tablets OTHERS COMBINATIONS Tramadol 37.5 mg + Paracetamol 325 mg + Domperidone 10mg Tramadol 37.5 mg + Paracetamol 325 mg + Aceclofenac 100 mg Tramadol Hcl + Paracetamol + Dicyclomine hcl Tramadol + Paracetamol + Diclofenac Tramadol + Paracetamol + Serratiopeptidase Chlorzoxazone + Tramadol

TRAMADOL 37.5 mg+ PARACETAMOL 325 mg + DOMPERIDONE 10mg

BRAND TRAMAZAC PD ULTRAMED D DOLOSAFE TACIL D TRAPIDOL D MERIDOL D ULTRAZAC D TOPSPAS D DISMOL DP TOLYDOL DOLOSPAN-DP

COMPANY ZYDUS CADILA PHARMED TIDAL CORONA REMEDIES JENBURKT UNIMARCK ZYDUS CADILA PSYCHOTROPICS GRANDIX IPCA EMCURE

Price (10s) 71.9 83 55.8 63.79 55.4

 Indications
Pre & post surgical cases. Chronic Disease conditions involving high oxidative stress such as diabetes mellitus, ischemic heart disease, COPD etc. Acts as an essential adjuvant in Chronic Bronchitis, Pneumonia, TB, Prostate Cancer, Cervical Cancer, Multiple Trauma & Burns.